Abstract
Lupus nephritis (LN) is severe renal comorbidity associated with systemic lupus erythematosus (SLE), a complex autoimmune disorder with high morbidity and mortality. Diagnosis and monitoring of LN patients still rely on renal biopsy, a procedure that exposes patients to a variety of risks and is not capable of providing longitudinally information about disease prognosis. In this review, we summarized current data of recent promising biomarkers developed in the precision medicine era, particularly under genomic, transcriptomic, proteomic, and metabolomic techniques. Genome-wide association studies have been evaluating the role of endogenous elements beyond the autoimmunity in LN. Transcriptomic methods, including single-cell sequencing, are potential tools in identifying inflammatory signatures, miRNAs, and gene expression. Proteomic measures, including anti-C1q antibodies, cytokines, TLRs, VCAM-1, NGAL osteopontin, angiostatin, have been considered helpful to provide a more profound comprehension of the disease pathogenic processes. Metabolomic approaches may identify several abnormal metabolite profiles related to the impairment of cellular functions. Together, these accurate, non-invasive, and moderate-cost propedeutic resources may be the novel tools for recognizing, distinguishing, and predicting LN progression and prognosis. Furthermore, omics evaluation may also predict responsiveness to treatment and, consequently, change the way we manage LN cases in the near future.
Keywords: Biomarkers, lupus nephritis, monitoring, diagnosis, therapeutic targets, genomics, transcriptomics, proteomics, metabolomics.
Current Medicinal Chemistry
Title:Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Volume: 28 Issue: 29
Author(s): Raphael Dias, Ursula Gramiscelli Hasparyk, Monisi Peres Lopes, João Luiz Vieira Monteiro de Barros and Ana Cristina Simões e Silva*
Affiliation:
- Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG,Brazil
Keywords: Biomarkers, lupus nephritis, monitoring, diagnosis, therapeutic targets, genomics, transcriptomics, proteomics, metabolomics.
Abstract: Lupus nephritis (LN) is severe renal comorbidity associated with systemic lupus erythematosus (SLE), a complex autoimmune disorder with high morbidity and mortality. Diagnosis and monitoring of LN patients still rely on renal biopsy, a procedure that exposes patients to a variety of risks and is not capable of providing longitudinally information about disease prognosis. In this review, we summarized current data of recent promising biomarkers developed in the precision medicine era, particularly under genomic, transcriptomic, proteomic, and metabolomic techniques. Genome-wide association studies have been evaluating the role of endogenous elements beyond the autoimmunity in LN. Transcriptomic methods, including single-cell sequencing, are potential tools in identifying inflammatory signatures, miRNAs, and gene expression. Proteomic measures, including anti-C1q antibodies, cytokines, TLRs, VCAM-1, NGAL osteopontin, angiostatin, have been considered helpful to provide a more profound comprehension of the disease pathogenic processes. Metabolomic approaches may identify several abnormal metabolite profiles related to the impairment of cellular functions. Together, these accurate, non-invasive, and moderate-cost propedeutic resources may be the novel tools for recognizing, distinguishing, and predicting LN progression and prognosis. Furthermore, omics evaluation may also predict responsiveness to treatment and, consequently, change the way we manage LN cases in the near future.
Export Options
About this article
Cite this article as:
Dias Raphael , Hasparyk Gramiscelli Ursula , Lopes Peres Monisi , de Barros Luiz Vieira Monteiro João and Simões e Silva Cristina Ana *, Novel Biomarkers for Lupus Nephritis in the “OMICS” Era, Current Medicinal Chemistry 2021; 28 (29) . https://dx.doi.org/10.2174/0929867328666210212102438
DOI https://dx.doi.org/10.2174/0929867328666210212102438 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Neurological Complications in Systemic Inflammatory Diseases
Current Rheumatology Reviews Prospective of Natural Gum Nanoparticulate Against Cardiovascular Disorders
Current Chemical Biology Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
Current Vascular Pharmacology An Approach to Psychiatric Illness in Rheumatology Clinics
Current Rheumatology Reviews Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Current Medicinal Chemistry Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Current Medicinal Chemistry Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Molecular Aspects of Drug Recognition by Specific T Cells
Current Drug Targets Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Disseminated Cryptococcosis in Idiopathic CD4+ Lymphocytopenia
Infectious Disorders - Drug Targets IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Pharmacological and Clinical Basis of Treatment of Familial Mediterranean Fever (FMF) with Colchicine or Analogues: An Update
Current Drug Targets - Inflammation & Allergy